Advertisement
U.S. markets open in 2 hours 46 minutes
  • S&P Futures

    5,307.25
    -1.00 (-0.02%)
     
  • Dow Futures

    40,150.00
    +6.00 (+0.01%)
     
  • Nasdaq Futures

    18,501.75
    -2.00 (-0.01%)
     
  • Russell 2000 Futures

    2,138.00
    -0.40 (-0.02%)
     
  • Crude Oil

    82.07
    +0.72 (+0.89%)
     
  • Gold

    2,228.60
    +15.90 (+0.72%)
     
  • Silver

    24.81
    +0.05 (+0.21%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.96
    +0.18 (+1.41%)
     
  • dólar/libra

    1.2617
    -0.0021 (-0.16%)
     
  • USD/JPY

    151.3880
    +0.1420 (+0.09%)
     
  • Bitcoin USD

    70,454.10
    +401.91 (+0.57%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,959.12
    +27.14 (+0.34%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year of 2020 after market close on Wednesday, February 24, 2021. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com


Advertisement